Bone Marrow & Stem Cell Transplant

Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic malignancies compared to traditional treatments.

New research reveals mismatched unrelated donors significantly improve transplant outcomes, expanding options for diverse patients in need of life-saving procedures.

MaaT013 shows promising efficacy and safety in treating refractory GI-aGVHD, offering hope for improved survival in patients.

New findings reveal the feasibility and safety of transitioning axatilimab dosing for chronic graft-vs-host disease, showing promising response rates.

During a live event, Hannah Choe, MD, discussed options for steroid-resistant cGVHD based on organ involvement, efficacy, and safety profiles.

Research reveals matched unrelated donor transplants significantly enhance survival rates in leukemia patients compared with haploidentical transplants, despite donor availability.

New response criteria for acute GVHD enhance prediction of nonrelapse mortality, potentially transforming clinical trial designs and treatment evaluations.

During a live event, Hannah Choe, MD, and event participants discuss steroid-dependent chronic GVHD, favoring adding therapy over increasing steroids.

New research highlights narsoplimab's potential to significantly reduce mortality in high-risk patients with thrombotic microangiopathy after stem cell transplants.

New research reveals that sustained MRD negativity after ASCT allows safe discontinuation of lenalidomide maintenance in multiple myeloma patients.

A recent study reveals that alternative donors for hematopoietic cell transplants yield similar success rates as fully matched donors, enhancing patient outcomes.

A new study reveals that optimized donor search algorithms significantly enhance transplant outcomes for patients, even with alternative donor sources.

A new study explores strategies to enhance survival rates for patients facing challenges in finding bone marrow donors, advocating for quicker alternative options.

A new trial reveals PTCy and abatacept significantly reduce chronic GVHD in stem cell transplant patients, offering promising outcomes over standard care.

A study reveals significant survival disparities in plasma cell leukemia, highlighting the benefits of stem cell transplantation for patient outcomes.

During a live event, Michael R. Bishop, MD, discussed a case of steroid-refractory GVHD and the efficacy and safety outcomes from the ROCKstar trial.

Research advances in blood cancer treatment enhance donor matching and reduce graft-vs-host disease, improving access to life-saving transplants for diverse patients.

With pegtarazimod and belumosudil advancing through the global pipeline, options are expanding for patients with GVHD worldwide.

New research identifies low counts of activated HLA-DR+CD3+ T cells as a potential biomarker for increased transplant-related mortality and severe chronic graft-versus-host disease.

During a live event, Michael R. Bishop, MD, discussed efficacy and safety outcomes from the AGAVE-201 trial.

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of outcomes for acute GVHD.

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and improving coping abilities.

A groundbreaking study enhances stem cell transplant access for diverse patients, improving outcomes with mismatched donors and innovative techniques.

FDA prioritizes review of tabelecleucel, a promising therapy for relapsed EBV+ PTLD, offering hope to patients with limited treatment options.